Varicella zoster virus vaccine live - GlaxoSmithKline

Drug Profile

Varicella zoster virus vaccine live - GlaxoSmithKline

Alternative Names: Chickenpox vaccine - GlaxoSmithKline; GSK-208133; Varilrix

Latest Information Update: 05 Jan 2017

Price : $50

At a glance

  • Originator Osaka University
  • Developer GlaxoSmithKline
  • Class Varicella vaccines; Viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Varicella zoster virus infections

Most Recent Events

  • 01 Oct 2016 GlaxoSmithKline Biologicals completes a phase III trial in Varicella zoster virus infections (In infants, Prevention) in Germany, Estonia, Mexico, Thailand and the UK (SC) (NCT02570126)
  • 13 Oct 2015 Phase-III clinical trials in Varicella zoster virus infections (In infants, Prevention) in Estonia (SC) after October 2015
  • 13 Oct 2015 Phase-III clinical trials in Varicella zoster virus infections (In infants, Prevention) in Germany (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top